Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Gooding, S; Ansari-Pour, N; Towfic, F; Estevez, MO; Chamberlain, PP; Tsai, KT; Flynt, E; Hirst, M; Rozelle, D; Dhiman, P; Neri, P; Ramasamy, K; Bahlis, N; Vyas, P; Thakurta, A

Thakurta, A (corresponding author), Bristol Myers Squibb, 556 Morris Ave, Summit, NJ 07901 USA.

BLOOD, 2021; 137 (2): 232

Abstract

Emergence of drug resistance to all available therapies is the major challenge to improving survival in myeloma. Cereblon (CRBN) is the essential bind......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索